Clene Nanomedicine’s RESCUE-ALS Phase 2 Results Selected for Late-Breaking Presentation at 32nd International Symposium on ALS/MND

NEXT STORY
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2022
PREV STORY
Ondine Biomedical appoints new Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China

Aptose adds China territory to its global rights; CrystalGenomics to receive upfront payment and ...

author_avatar
NASDAQ Market News

CrownBio Supports Excellence in Translational Research with Grant Award that Funds Innovative PDX Model Development in Immuno-Oncology

"Cancer Research Center of Lyon iPS novel PDX models formulate new immune cell focused ...

author_avatar
NASDAQ Market News

Hospital Pharmaceuticals Market to Account for US$280.3 bn by 2023; Oncology Constituted Largest Indication Segment in 2014:Transparency Market Research

Albany, NY, May 24, 2016 (GLOBE NEWSWIRE) -- Transparency Market Research has published a ...

author_avatar
NASDAQ Market News